These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5571352)

  • 1. Concentration of propoxyphene in human plasma following repeated oral doses.
    Wolen RL; Gruber CM; Kiplinger GF; Scholz NE
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):493-7. PubMed ID: 5571352
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of plasma concentrations of propoxyphene utilizing a hybrid principal component-analysis of variance technique. Case 1--equimolar doses.
    Rodda BE; Scholz NE; Gruber CM; Wolen RL
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):554-62. PubMed ID: 4937002
    [No Abstract]   [Full Text] [Related]  

  • 3. The concentration of propoxyphene in the plasma and analgesia scores in postpartum patients.
    Wolen RL; Gruber CM; Baptisti A; Scholz NE
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):498-503. PubMed ID: 5106308
    [No Abstract]   [Full Text] [Related]  

  • 4. A study of propoxyphene and salicylate concentrations in human plasma following the administration of propoxyphene napsylate and aspirin.
    Nash JF; Scholz NE; Maxwell SB
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):537-45. PubMed ID: 5571353
    [No Abstract]   [Full Text] [Related]  

  • 5. Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration.
    Wolen RL; Gruber CM; Kiplinger GF; Scholz NE
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):480-92. PubMed ID: 4936997
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute toxicity of propoxyphene salts.
    Emmerson JL; Gibson WR; Anderson RC
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):445-51. PubMed ID: 5571349
    [No Abstract]   [Full Text] [Related]  

  • 7. Analgesia scores as timed responses following oral administration of propoxyphene to postpartum patients.
    Gruber CM; Wolen RL; Baptisti A
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):504-11. PubMed ID: 4936998
    [No Abstract]   [Full Text] [Related]  

  • 8. Relief of postpartum uterine cramping with propoxyphene and aspirin.
    Gruber CM; Baptisti A; Kiplinger GF
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):546-53. PubMed ID: 5106309
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of plasma concentrations of propoxyphene utilizing a hybrid principal component-analysis of variance technique. Case II--equipotent doses.
    Rodda BE; Scholz NE; Gruber CM; Wolen RL
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):563-71. PubMed ID: 4937003
    [No Abstract]   [Full Text] [Related]  

  • 10. d-Propoxyphene kinetics after single oral and intravenous doses in man.
    Gram LF; Schou J; Way WL; Heltberg J; Bodin NO
    Clin Pharmacol Ther; 1979 Oct; 26(4):473-82. PubMed ID: 487695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of radiocarbon-labeled propoxyphene in rat, dog, and human.
    McMahon RE; Ridolfo AS; Culp HW; Wolen RL; Marshall FJ
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):427-44. PubMed ID: 5571348
    [No Abstract]   [Full Text] [Related]  

  • 12. The effectiveness and side-effect liability of propoxyphene hydrochloride and propoxyphene napsylate in patients with postpartum uterine cramping.
    Baptisti A; Gruber CM; Santos EL
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):519-27. PubMed ID: 4937000
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of first-pass effect on the systemic availability of propoxyphene.
    Perrier D; Gibaldi M
    J Clin Pharmacol New Drugs; 1972; 12(11):449-52. PubMed ID: 4484660
    [No Abstract]   [Full Text] [Related]  

  • 14. The analgesic activity of propoxyphene napsylate with and without aspirin.
    Wang RI; Sandoval RG
    J Clin Pharmacol New Drugs; 1971; 11(4):310-7. PubMed ID: 4932749
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma concentrations of propoxyphene in man. I. Following oral administration of the drug in solution and capsule forms.
    Wagner JG; Welling PG; Roth SB; Sakmar E; Lee KP; Walker JE
    Int Z Klin Pharmakol Ther Toxikol; 1972 Feb; 5(4):371-80. PubMed ID: 4558245
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma concentrations of propoxyphene in man. II. Pharmacokinetics.
    Wagner JG; Welling PG; Sedman AJ
    Int Z Klin Pharmakol Ther Toxikol; 1972 Feb; 5(4):381-8. PubMed ID: 5046052
    [No Abstract]   [Full Text] [Related]  

  • 17. Analgesia, plasma levels, and dosage of propoxyphene.
    Waife SO; Gruber CM; Rodda BE; Nash JF
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):177-81. PubMed ID: 950259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effects of chronic administration of propoxyphene salts to normal volunteers.
    Kiplinger GF; Gruber CM; Pierce EC
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):528-36. PubMed ID: 4937001
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous estimation of propoxyphene-do and propoxyphene-d2 levels by quantitative mass fragmentography. Potential utility in multidose investigations.
    Sullivan HR; Wood PG; McMahon RE
    Biomed Mass Spectrom; 1976 Oct; 3(5):212-6. PubMed ID: 974235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography.
    Wolen RL; Ziege EA; Gruber CM
    Clin Pharmacol Ther; 1975 Jan; 17(1):15-20. PubMed ID: 1122667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.